The regulation of cell death in activated naïve T cells is not well understood. We examined the expression of A1, an anti-apoptotic member of the Bcl-2 family, following activation of naïve mouse splenocytes. A1 gene expression was strongly but transiently induced during the first day of activation, with a peak at 2 to 6 hours, while Bcl-2 mRNA was simultaneously transiently downregulated.
Introduction
Activation of T cells via the TCR can lead either to proliferation and differentiation or alternatively to apoptotic cell death. This critical decision is regulated by contextual factors such as the presence of costimulatory signals and cytokines as well as prior activation of the cell [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Studies with T cell lines indicate that a component of this regulation is the ability of the activated cell to impede apoptotic signalling mediated by death receptors such as Fas 12, 13 . In cultures of primary T cells, a Fas-dependent pathway of "activation-induced cell death" has been demonstrated in cells subject to repeated stimulation 4, 14, 15 . Similarly, the expansion of T cells activated in vivo by high levels of antigen (in the absence of adjuvant) is limited by the Fas and/or TNFα-dependent removal of these cells [16] [17] [18] .
However the initial activation of naïve T cells in natural antigen responses may involve a different set of survival-regulatory mechanisms. Polyclonal activation of cultured naïve T cells leads to Fasindependent apoptosis 6 . Furthermore the homeostatic contraction of the response of adoptively transferred TCR-transgenic T cells is Fas-independent when the antigen is provided locally with adjuvant rather than systemically 18 . Similarly the response of naïve donor T cells to alloantigen in vivo leads to Fas-independent apoptosis 19 , as does the activation of Vβ8 + T cells in vivo by staphylococcal enterotoxin B 20 .
The induction of apoptosis following activation of naïve T cells appears to be counterbalanced by antiapoptotic mechanisms that are active for at least one to several days after exposure to antigen. In vivo studies of both Fas-independent death after alloantigen stimulation and Fas-dependent death using superantigen indicate that activated cells enter apoptosis only after cell division has occurred 21, 22 .
Similarly, another study of apoptosis induced in naïve cells in vivo by superantigen found that during only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013 . bloodjournal.hematologylibrary.org From the first 1-2 days T cells did not enter apoptosis and were Fas-resistant 23 . Moreover at day 1 of the response these activated death-resistant cells experienced a transient elevation of Bax, a pro-apoptotic member of the Bcl-2 family of survival-regulatory proteins. This finding suggests that activated cells at this early stage have a mechanism of resisting Bax-induced death. More recently Bim, a member of the BH3-only pro-apoptotic branch of the Bcl-2 family, has been shown to be upregulated by TCR ligation in thymocytes and to play an essential role in the apoptosis that ensues 24 . Bim has also been shown to be required for the deletion of Vβ8+ T cells following activation in vivo with a superantigen 20 . Studies of mice that are deficient in either Bax or a third pro-apoptotic family member, Bak, have shown that either Bax or Bak is essential for spontaneous cell death in unstimulated T cells 25 ,for which Bim is also necessary 26 , and thus it is conceivable that all of these Bcl-2-related proteins may contribute to a cell death pathway activated following exposure of naïve cells to antigen. Consistent with this idea, when the expression of Bcl-2, an anti-apoptotic protein that can counteract the activity of these proapoptotic molecules , was eliminated by gene targeting, naïve T cells showed increased apoptosis that peaked at 24 h after activation by anti-CD3 27 . Bcl-2 can protect lymphoctyes from a variety of apoptotic stimuli, although not from the activation of death receptors such as Fas 28, 29 . However Bcl-2, while constitutively present in quiescent naïve T cells, does not show increased expression during the first few days following polyclonal T cell activation in vitro 6, 30, 31 , although it can be induced by the addition of IL-2 30, 32 . At least four additional anti-apoptotic members of the Bcl-2 family (Bcl-xL, A1,
Mcl-1, Bcl-w) have the capacity to interfere with Bax-induced cell death [33] [34] [35] . Of these, Bcl-xL protein expression has been shown to be induced during the first day following activation of naïve T cells with anti-CD3. Co-stimulation via CD28 greatly increases expression and also provides extensive protection from apoptosis 6, 7, [36] [37] [38] [39] [40] [41] [42] .
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The A1 gene is also expressed in the T cell lineage 43, 44 and is upregulated by activation 45, 46 . A1 is induced as an immediate-early gene by activating stimuli in macrophages 43 . In Toxoplasma gondiielicited inflammatory macrophages the induction of A1 in vivo parallels that of pro-apoptotic Bax 47 .
We therefore asked whether A1 plays a role in the survival of freshly activated T cells. We found that A1 is strongly and transiently upregulated very early after activation of naïve cells. Furthermore transgenic A1, unlike Bcl-2, is able to protect T cells without interfering with cell cycle progression, and thus may represent a unique adaptation of an anti-apoptotic strategy to the onset of proliferative activation.
only. RNA analysis. Cells were pelleted and total RNA extracted with Trizol (Life Technologies, Rockville, MD) according to the manufacturer's instructions, with the addition of an ethanol precipitation step after isopropanol precipitation. Northern blot analysis of A1 and Bcl-2 expression and normalization to 28S rRNA levels using a PhosphorImager™ (Molecular Dynamics, Sunnyvale, CA) were as previously described 47 . RT-PCR analysis of A1 isoforms was performed according to the method of Hatekayama et al. 52 . RNase protection analysis was performed on 1 ug of total cellular RNA using the Riboquant system (BD Pharmingen) as previously described 53 .
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Cell debris, doublets and aggregates were gated out using a doublet discrimination module (Becton 
Results

Induction of A1 mRNA during T cell activation.
We investigated the expression of Bcl-2 family members following Con A activation of fresh splenocytes from naïve animals. As shown in Figure 1A , A1 mRNA was increased 14-fold within 6 h after stimulation and then rapidly returned to baseline levels by day 3. RT-PCR analysis (not shown) indicated that all A1 isoforms were induced, although the fold induction was greatest for the A1-a isoform. In contrast, Bcl-2 mRNA levels were repressed during the first day of activation but had begun to rebound by 24 h (Fig. 1B) . A similar induction was observed when purified splenic T cells were activated with αCD3 + αCD28 (Fig. 1C) . To investigate the potential role of A1 in T cell survival we constructed A1-a Tg strains in which the distal lck promoter was used to direct expression to the T cell lineage. Four independently generated A1-a Tg lines were analyzed for transgene mRNA expression in thymus and spleen. Three lines had similar high levels of expression; two of these lines (6.3 and 7.1) were chosen for further investigation.
As shown in Figure 2 , the transgene produces multiple RNA species, several of which are clustered between 1.6 -3.0 kb. The 1.6 kb band at the lower end of this cluster agrees with the predicted size of the fully spliced transgenic transcript, while 3.0 kb is the predicted size of the primary transcript.
Similar clusters have been observed in previous studies using this vector and are likely due to alternative or incomplete splicing of the human growth hormone component of the transcript 49, 54 . only.
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Increased cellularity of lymphoid organs in A1-a-transgenic mice.
Thymi and spleens collected from A1-a Tg mice had greater cellularity than control littermates (Fig. 3) .
We did not observe a difference in the relative proportions of CD4 or CD8 single-positive or doublepositive subsets in either thymus or spleen (data not shown). 
Resistance to spontaneous and induced cell death in A1 Tg mouse thymocytes.
Initially we examined the anti-apoptotic activity of the A1-a transgene in thymocytes, as this cell type
has been frequently used to analyze the effects of Bcl-2 and Bcl-xL transgenes. Thymocytes overexpressing either Bcl-2 or Bcl-xL show reduced spontaneous apoptosis in culture as well as resistance to cell death induced by agents such as ionizing radiation, glucocorticoids, and ionomycininduced cell death 28, 55, 56 . As shown in Fig. 4 , the A1-a transgene inhibited spontaneous thymocyte apoptosis. By day 7 all the wild-type thymocytes were dead, whereas 30% of the A1-a Tg cells remained viable (data not shown). An increase in the proportion of double-positive CD4 + CD8 + thymocytes was noted by day 4 in the transgenic cultures (data not shown). A1-a Tg thymocytes were only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From partially protected from cell death induced by either dexamethasone, ionomycin or gamma-irradiation (Fig. 4A -C) . In contrast no protection was observed in cultures treated with αFas + cycloheximide. In the absence of cycloheximide, a modest induction of apoptosis by αFas was reproducibly observed over 9 experiments, and a consistent small inhibition of this death was observed in A1-a Tg cells (Fig.   4A ). However the degree of inhibition was no greater than the inhibition of spontaneous apoptosis, so that no conclusion could be drawn regarding a protective effect of the transgene. Overall this pattern of anti-apoptotic activity in thymocytes is similar to previous studies of Bcl-2 and Bcl-xL-transgenic cells 28, 55 . 
A1-a protects activated splenocytes from apoptosis.
We next assessed the effect of Tg A1-a on the apoptosis of splenocytes either cultured in control medium or activated with the T cell specific mitogen Con A (Fig. 5) . Tg A1-a reduced the frequency of spontaneous cell death in control cultures by about half. CD4 + and CD8 + subsets were protected to similar extents (data not shown). Con A-treated wild-type cells showed significantly only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From reduced apoptosis during the first day, corresponding to the period of endogenous A1 gene expression observed in Fig. 1 . The expression of the A1-a transgene produced a modest but significant degree of additional protection at day 1. Continued culture of wild-type cells in Con A (during which endogenous A1 gene expression returns to baseline [ Fig. 1]) led to sharply increased apoptosis. Tg A1-a remained protective throughout the culture, and by day 5 the Tg A1-a-induced inhibition of apoptosis had increased to 41 per cent. This protection of activated cells is reflected in the accumulation of viable cells following activation (Fig. 5B) . A significant difference between control and A1 Tg viable cell number became apparent by day 3 after activation and this difference increased at later time points. We next sought to confirm these results using a second apoptosis assay method (annexin binding) that permitted specifc analysis of T cells. In this experiment the splenocytes were activated with αCD3 + αCD28 in order to verify that the effect of the A1-a transgene was not limited to mitogenstimulated cells. Once again we observed that Tg A1-a inhibited apoptosis throughout the post-activation period, and that this inhibition was especially prominent at day 5, at which point a pronounced increase in T cell yield became evident (Fig. 6) . 
A1-a does not protect T cells from death induced by restimulation of the TCR.
Apoptosis associated with the initial actiation of naïve T cells is thought to take place via a Fasindependent mechanism 6 . In contrast, restimulation 
Overexpression of A1, unlike Bcl-2, does not inhibit the proliferation of activated T cells.
only. only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From treatment was increased 93% by the A1-a transgene, but only 49% by the Bcl-2 transgene. Similar differences between Tg A1-a and Tg Bcl-2 splenocyte accumulation were observed in two additional experiments in which unfractionated cells were assessed (data not shown). These results might reflect differential effects of the two transgenes on either T cell survival or proliferation. As shown in Fig. 9 , the overall effectiveness of Tg Bcl-2 as an anti-apoptotic agent in either resting or activated T cells was similar to that of Tg A1-a. Similarly, there was no difference between the two transgenes with respect to viable T cell accumulation in unstimulated cultures (Fig. 8B) . Therefore it is unlikely that the differential effect of the transgenes on T cell accumulation is due to either a difference in transgene expression or a general difference in the apoptotic mechanisms affected. One possibility is that a specific apoptotic mechanism generated after activation is inhibited more efficiently by Tg A1-a than by Tg Bcl-2. The variability of the data in Fig. 9B do not permit a definitive answer to this question. A second possibility is that the transgenes differentially affect T cell proliferation. It has been shown that transgenic overexpression of Bcl-2 in T cells can delay cell cycle progression following activation 27, 58, 59 . Figure 10 confirms this finding. In contrast cell cycle progression was not affected by Tg A1-a after activation with either Con A or plate-bound αCD3. 
Discussion
Evidence from several model systems of T cell activation supports the notion that the activated cell moves through an early period of death resistance followed by a period of increased susceptibility to apoptosis. This window of resistance might reflect either a delay in the onset of pro-apoptotic signals or the temporary provision of an anti-apoptotic mechanism. The latter model is supported by recent studies showing early upregulation of pro-apoptotic factors (Fas, fasL, bad, bax, bim) in activated cells 23, 24 , as well as by several studies demonstrating induction of Bcl-xL expression within one day of activation 6, 7, 40 . Our results lend further support to this view by showing that an early event after activation is a strong, transient increase in A1 gene expression. A caveat is that this expression has not been verified at the protein level, and recent studies have found discordance between mRNA and protein expression for Bcl-2 31,60-62 as well as for several pro-apoptotic family members 63, 64 . These results may be related to the relatively stability of these proteins 61, 63, 65 ; in contrast, A1 has been reported to have a short half-life 65 consistent with its pattern of acute regulation. Our findings suggest that A1, perhaps in concert with Bcl-xL and other unknown factors, may act to generate the deathresistant window, and also that the subsequent downregulation of A1 may contribute to a stage of increased post-activation apoptosis.
To investigate these ideas further, we generated strains of transgenic mice in which the A1-a isoform of A1 is overexpressed in T cells. The A1-a transgene was strongly expressed in both thymocytes and splenocytes and provided protection from apoptosis to quiescent cells from both tissues, similar to previous studies of the effects of transgenic Bcl-2 and Bcl-xL 2 7, 55 . Tg A1-a and Tg Bcl-2 were quantitatively comparable with respect to protection of resting splenic T cells from spontaneous only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From apoptosis in culture. After Con A activation, however, the yield of viable T cells was significantly greater with Tg A1-a than with Tg Bcl-2. We were able to relate this finding to the fact that Tg A1-a had no effect on the cell cycle status of T cells activated with either Con A or αCD3, whereas Tg Bcl-2 reduced the proliferative index by about half 48 h after either stimulus.
These results suggest a model in which activated T cells progress through successive stages that are characterized by distinct anti-apoptotic mechanisms. In particular, in view of the evidence that during the first day after activation T cells move through cell cycle transition points that are sensitive to Bcl-2 27, 58 , it is logical to hypothesize that at this stage Bcl-2 is repressed and A1 activated. A caveat to this idea is that alterations of T cell Bcl-2 mRNA level do not always correspond to changes in protein expression 40 , perhaps due to the relatively long half-life of Bcl-2 protein compared to A1 65 . However a study of Bcl-2 protein expression in human PBL found evidence of reduced expression during the first day after activation 31 . In addition it is possible that Bcl-2 repression may include both a transcriptional and a post-translational component, as a recent report indicates that the cell-cycle inhibitory effects of Bcl-2 protein can be specifically blocked by phosphorylation mediated by cyclindependent kinases 66 . In any case the postulated repression of Bcl-2 cannot be complete, since removal of endogenous Bcl-2 was shown to accelerate S-phase entry in αCD3-activated splenocytes 27 . In the latter study an inhibitory effect of endogenous Bcl-2 on IL-2 gene transcription was evident as early as 1h after activation, suggesting that even if our model is correct, the 'A1 for Bcl-2' switch may not occur rapidly enough to prevent a degree of inhibition.
Our model suggests that after the first day of activation, A1 may be replaced by other survival regulators, such as Bcl-2 or Bcl-xl. This transition might be mediated by IL-2, which can both induce only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From Bcl-2 and downregulate A1 gene expression 30, 32 . The anti-proliferative effects of Bcl-2 and Bcl-xL 59 might be minimized once the sensitive stage of the initial cell cycle has been traversed. At least in the case of Bcl-2 this seems likely, as the sensitive control point appears to be NF-AT-mediated IL-2 transcription 27 , and this transcription subsequently becomes NF-AT-independent 67 . Bcl-xL, however, is induced during the first day of activation 6, 7, 40 , and the mechanism of its cell cycle-inhibitory effects have been less well characterized. It would be helpful to compare the kinetics of induction of the A1
and Bcl-xL proteins. This analysis has been prevented to date by the insensitivity of A1 protein assays.
The notion that after the first day other Bcl-2 family members replace A1 might seem to be in conflict with our suggestion that the decline in endogenous A1 expression contributes to the acceleration of post-activation apoptosis. However Bcl-2 protein expression is highly heterogeneous for several days after splenocyte activation 30 , and thus may be protective of only a selected subset of activated cells. It will be of interest to determine whether activation-induced A1 protein expression is comparatively more homogeneous. Alternatively, A1 may function to counteract certain pro-apoptotic signals generated during activation and against which Bcl-2 is less effective. In this case the downregulation of endogenous A1 may be essential in order to permit apoptosis necessary for the focussing or resolution of the immune response, or for the elimination of self-reactive cells. Comparative studies of the apoptotic pathways affected by Tg A1-a and Tg Bcl-2 may address this issue.
Relatively few studies have indicated functional distinctions among anti-apoptotic Bcl-2 family members, particularly with regard to functions other than cell survival. We previously reported that the spontaneous granulocytic differentiation of 32D cells was inhibited by Bcl-2 but not by A1 68 . The biochemical basis for a functional disparity between these two molecules is unknown. The N-terminal only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From BH4 region of Bcl-2 has been shown to specifically mediate the anti-proliferative rather than the antiapoptotic effects of the protein 69 . Interestingly, mouse A1 lacks a BH4 region and shows no sequence similarity to other family members in this region.
In vivo studies indicate that the post-activation apoptosis of previously naïve T cells occurs as a highly regulated physiological process dependent on cell division and IL-2 signalling 21, 22 . A recent study indicated that CD4+ splenocytes activated in vitro also undergo apoptosis via a mechanism that is 'metered' by cell division 70 . The immunological properties, if any, that distinguish apoptotic and surviving cells at this juncture are unknown. Consequently it is as yet unclear whether this phenomenon represents a general homeostatic dampening of the activated population or a more specific tailoring of the immune response. A study of the retention of adoptively transferred TCRtransgenic T cells after immunization showed enhanced retention of Tg Bcl-2 donor cells, indicating that post-activation apoptosis in vivo is susceptible to modulation by Bcl-2 family members 18 . A comparative analysis of the effects of Bcl-2 family member transgenes on T cell kinetics in vivo should help to evaluate the hypotheses generated by the current study.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From
